Comparison of the Prognosis and Outcome of Heart Failure With Reduced Ejection Fraction Patients Treated With sacubitril/valsartan According to Age

References

• Wang TJ , EvansJC, BenjaminEJ, LevyD, LeRoyEC, VasanRS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation, 108(8), 977–982 (2003).
   PubMed Web of Science ®Google Scholar
• Askoxylakis V , ThiekeC, PlegerSTet al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer, 10(105), 1–8 (2010).
   PubMedGoogle Scholar
• Investigators S , YusufS, PittB, DavisCE, HoodWB, CohnJN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med., 325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA , SwedbergK, GrangerCBet al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the charm-overall programme. Lancet, 362(9386), 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B , ZannadF, RemmeWJet al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med., 341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Hjalmarson A , GoldsteinS, FagerbergBet al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol cr/xl randomized intervention trial in congestive heart failure (merit-hf). Merit-hf study group. JAMA, 283(10), 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Swedberg K , KomajdaM, BohmMet al. Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet, 376(9744), 875–885 (2010).
   PubMed Web of Science ®Google Scholar
• McMurray JJV , SolomonSD, InzucchiSEet al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381(21), 1995–2008 (2019).
   PubMed Web of Science ®Google Scholar
• Antiarrhythmics versus Implantable Defibrillators, I . A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med., 337(22), 1576–1583 (1997).
   PubMed Web of Science ®Google Scholar
• Jankowska EA , TkaczyszynM, SuchockiTet al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur. J. Heart Fail., 18(7), 786–795 (2016).
   PubMed Web of Science ®Google Scholar
• Rademaker MT , CharlesCJ, EspinerEA, NichollsMG, RichardsAM, KosoglouT. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin ii. J. Cardiovasc. Pharmacol., 31(1), 116–125 (1998).
   PubMed Web of Science ®Google Scholar
• Trippodo NC , FoxM, MonticelloTM, PanchalBC, AsaadMM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ace inhibition with captopril. J. Cardiovasc. Pharmacol., 34(6), 782–790 (1999).
   PubMed Web of Science ®Google Scholar
• Abumayyaleh M , El-BattrawyI, BehnesM, BorggrefeM, AkinI. Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiol., 16(4), 227–236 (2020).
   PubMed Web of Science ®Google Scholar
• Rademaker MT , CharlesCJ, EspinerEA, NichollsMG, RichardsAM, KosoglouT. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin. Sci. (Lond)., 91(3), 283–291 (1996).
   PubMed Web of Science ®Google Scholar
• Matsuo A , Nagai-OkataniC, NishigoriM, KangawaK, MinaminoN. Natriuretic peptides in human heart: novel insight into their molecular forms, functions, and diagnostic use. Peptides, 111, 3–17 (2019).
   PubMed Web of Science ®Google Scholar
• Maisel AS , DuranJM, WetterstenN. Natriuretic peptides in heart failure: atrial and b-type natriuretic peptides. Heart Fail. Clin., 14(1), 13–25 (2018).
   PubMed Web of Science ®Google Scholar
• Gu J , NoeA, ChandraPet al. Pharmacokinetics and pharmacodynamics of lcz696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (arni). J. Clin. Pharmacol., 50(4), 401–414 (2010).
   PubMed Web of Science ®Google Scholar
• Hegde LG , YuC, RennerTet al. Concomitant angiotensin at1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J. Cardiovasc. Pharmacol., 57(4), 495–504 (2011).
   PubMed Web of Science ®Google Scholar
• McMurray JJ , PackerM, DesaiASet al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 371(11), 993–1004 (2014).
   PubMed Web of Science ®Google Scholar
• Yancy CW , JessupM, BozkurtBet al. 2016 acc/aha/hfsa focused update on new pharmacological therapy for heart failure: an update of the 2013 accf/aha guideline for the management of heart failure: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america. J. Am. Coll. Cardiol., 68(13), 1476–1488 (2016).
   PubMed Web of Science ®Google Scholar
• Ponikowski P , VoorsAA, AnkerSDet al. 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc)developed with the special contribution of the heart failure association (hfa) of the esc. Eur. Heart J., 37(27), 2129–2200 (2016).
   PubMed Web of Science ®Google Scholar
• Almufleh A , MarbachJ, ChihSet al. Ejection fraction improvement and reverse remodeling achieved with sacubitril/valsartan in heart failure with reduced ejection fraction patients. Am. J. Cardiovasc. Dis., 7(6), 108–113 (2017).
   PubMedGoogle Scholar
• Martens P , BelienH, DupontM, VandervoortP, MullensW. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc. Ther., 36(4), e12435 (2018).
   PubMed Web of Science ®Google Scholar
• Martens P , NuyensD, Rivero-AyerzaMet al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin. Res. Cardiol., 108(10), 1074–1082 (2019).
   PubMed Web of Science ®Google Scholar
• Desai AS , McMurrayJJ, PackerMet al. Effect of the angiotensin-receptor-neprilysin inhibitor lcz696 compared with enalapril on mode of death in heart failure patients. Eur. Heart J., 36(30), 1990–1997 (2015).
   PubMed Web of Science ®Google Scholar
• Alagiakrishnan K , BanachM, JonesLG, AhmedA, AronowWS. Medication management of chronic heart failure in older adults. Drugs Aging, 30(10), 765–782 (2013).
   PubMed Web of Science ®Google Scholar
• Rengo F , AcanforaD, TrojanoLet al. Congestive heart failure in the elderly. Arch. Gerontol. Geriatr., 23(3), 201–223 (1996).
   PubMed Web of Science ®Google Scholar
• Jhund PS , FuM, BayramEet al. Efficacy and safety of lcz696 (sacubitril-valsartan) according to age: insights from paradigm-hf. Eur. Heart J., 36(38), 2576–2584 (2015).
   PubMed Web of Science ®Google Scholar
• Sieber CC . [The elderly patient - who is that?]. Internist (Berl.), 48(11), 1190, 1192–1194 (2007).
   PubMed Web of Science ®Google Scholar
• Teixeira A , ParenicaJ, ParkJJet al. Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. Eur. J. Heart Fail., 17(11), 1114–1123 (2015).
   PubMed Web of Science ®Google Scholar
• Group, CTS . Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (consensus). N. Engl. J. Med., 316(23), 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• Vergaro G , GhionzoliN, InnocentiLet al. Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction. J. Am. Heart Assoc., 8(20), e013441 (2019).
   PubMed Web of Science ®Google Scholar
• Chang HY , FengAN, FongMCet al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J. Cardiol., 74(4), 372–380 (2019).
   PubMed Web of Science ®Google Scholar
• Lluri G , LinJ, ReardonL, MinerP, WhalenK, AboulhosnJ. Early experience with sacubitril/valsartan in adult patients with congenital heart disease. World J. Pediatr. Congenit. Heart Surg., 10(3), 292–295 (2019).
   PubMed Web of Science ®Google Scholar
• Ambrosy AP , BraunwaldE, MorrowDAet al. Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists. J. Am. Coll. Cardiol., 76(9), 1034–1048 (2020).
   PubMed Web of Science ®Google Scholar
• Massari F , ScicchitanoP, IacovielloMet al. Multiparametric approach to congestion for predicting long-term survival in heart failure. J. Cardiol., 75(1), 47–52 (2020).
   PubMed Web of Science ®Google Scholar
• Damman K , GoriM, ClaggettBet al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail., 6(6), 489–498 (2018).
   PubMed Web of Science ®Google Scholar
• Spannella F , MariniM, GiuliettiFet al. Renal effects of sacubitril/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.. Intern. Emerg. Med., 14(8), 1287–1297 (2019).
   PubMed Web of Science ®Google Scholar
• Voors AA , GoriM, LiuLCet al. Renal effects of the angiotensin receptor neprilysin inhibitor lcz696 in patients with heart failure and preserved ejection fraction. Eur. J. Heart Fail., 17(5), 510–517 (2015).
   PubMed Web of Science ®Google Scholar
• Masarone D , MelilloE, ErrigoV, ValenteF, PacileoG. Clinical relevance of transient worsening renal function after initiation of sacubitril/valsartan. Curr. Med. Res. Opin., 37(1), 9–12 (2021).
   PubMed Web of Science ®Google Scholar
• de Diego C , Gonzalez-TorresL, NunezJMet al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm, 15(3), 395–402 (2018).
   PubMed Web of Science ®Google Scholar
• Kobayashi M , DouairA, DuarteKet al. Diagnostic performance of congestion score index evaluated from chest radiography for acute heart failure in the emergency department: a retrospective analysis from the paradise cohort. PLoS Med., 17(11), e1003419 (2020).
   PubMed Web of Science ®Google Scholar
• Metra M , DavisonB, BettariLet al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ. Heart Fail., 5(1), 54–62 (2012).
   PubMed Web of Science ®Google Scholar
• Lala A , McNultySE, MentzRJet al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (dose-ahf) and cardiorenal rescue study in acute decompensated heart failure (caress-hf). Circ. Heart Fail., 8(4), 741–748 (2015).
   PubMed Web of Science ®Google Scholar
• Chioncel O , MebazaaA, MaggioniAPet al. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the esc-eorp-hfa heart failure long-term registry. Eur. J. Heart Fail., 21(11), 1338–1352 (2019).
   PubMed Web of Science ®Google Scholar